202 related articles for article (PubMed ID: 18992959)
21. Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.
Tokumo M; Toyooka S; Ichihara S; Ohashi K; Tsukuda K; Ichimura K; Tabata M; Kiura K; Aoe M; Sano Y; Date H; Shimizu N
Lung Cancer; 2006 Jul; 53(1):117-21. PubMed ID: 16730855
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
Ichihara E; Hotta K; Nogami N; Kuyama S; Kishino D; Fujii M; Kozuki T; Tabata M; Harada D; Chikamori K; Aoe K; Ueoka H; Hosokawa S; Bessho A; Hisamoto-Sato A; Kubo T; Oze I; Takigawa N; Tanimoto M; Kiura K
J Thorac Oncol; 2015 Mar; 10(3):486-91. PubMed ID: 25695221
[TBL] [Abstract][Full Text] [Related]
23. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
Inoue A; Suzuki T; Fukuhara T; Maemondo M; Kimura Y; Morikawa N; Watanabe H; Saijo Y; Nukiwa T
J Clin Oncol; 2006 Jul; 24(21):3340-6. PubMed ID: 16785471
[TBL] [Abstract][Full Text] [Related]
24. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
[TBL] [Abstract][Full Text] [Related]
25. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
Kosaka T; Yatabe Y; Endoh H; Yoshida K; Hida T; Tsuboi M; Tada H; Kuwano H; Mitsudomi T
Clin Cancer Res; 2006 Oct; 12(19):5764-9. PubMed ID: 17020982
[TBL] [Abstract][Full Text] [Related]
26. Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
Morita S; Okamoto I; Kobayashi K; Yamazaki K; Asahina H; Inoue A; Hagiwara K; Sunaga N; Yanagitani N; Hida T; Yoshida K; Hirashima T; Yasumoto K; Sugio K; Mitsudomi T; Fukuoka M; Nukiwa T
Clin Cancer Res; 2009 Jul; 15(13):4493-8. PubMed ID: 19531624
[TBL] [Abstract][Full Text] [Related]
27. EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer.
Weber B; Hager H; Sorensen BS; McCulloch T; Mellemgaard A; Khalil AA; Nexo E; Meldgaard P
Lung Cancer; 2014 Feb; 83(2):224-30. PubMed ID: 24388704
[TBL] [Abstract][Full Text] [Related]
28. Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
Asami K; Koizumi T; Hirai K; Ameshima S; Tsukadaira A; Morozumi N; Morikawa A; Atagi S; Kawahara M
Clin Lung Cancer; 2011 Nov; 12(6):387-92. PubMed ID: 21729650
[TBL] [Abstract][Full Text] [Related]
29. Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
Dongiovanni D; Daniele L; Barone C; Dongiovanni V; Fissore C; Sapino A; Macrì L; Bussolati G; Buffoni L; Gaspari F; Grillo R; Birocco N; Addeo A; Ciuffreda L; Schena M
Lung Cancer; 2008 Jul; 61(1):73-81. PubMed ID: 18243402
[TBL] [Abstract][Full Text] [Related]
30. First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small-cell lung cancer patients treated in Taiwan.
Lie CH; Chang HC; Chao TY; Chung YH; Wang JL; Wang CC; Lin MC
Clin Lung Cancer; 2011 Mar; 12(2):116-24. PubMed ID: 21550558
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.
Lara-Guerra H; Waddell TK; Salvarrey MA; Joshua AM; Chung CT; Paul N; Boerner S; Sakurada A; Ludkovski O; Ma C; Squire J; Liu G; Shepherd FA; Tsao MS; Leighl NB
J Clin Oncol; 2009 Dec; 27(36):6229-36. PubMed ID: 19884551
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation.
Igawa S; Kasajima M; Ishihara M; Kimura M; Hiyoshi Y; Asakuma M; Otani S; Katono K; Sasaki J; Masuda N
Oncology; 2014; 87(4):215-23. PubMed ID: 25034225
[TBL] [Abstract][Full Text] [Related]
33. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
Mitsudomi T; Kosaka T; Endoh H; Horio Y; Hida T; Mori S; Hatooka S; Shinoda M; Takahashi T; Yatabe Y
J Clin Oncol; 2005 Apr; 23(11):2513-20. PubMed ID: 15738541
[TBL] [Abstract][Full Text] [Related]
34. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.
Oh IJ; Ban HJ; Kim KS; Kim YC
Lung Cancer; 2012 Jul; 77(1):121-7. PubMed ID: 22333554
[TBL] [Abstract][Full Text] [Related]
35. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.
Wu JY; Yu CJ; Shih JY; Yang CH; Yang PC
Lung Cancer; 2010 Mar; 67(3):348-54. PubMed ID: 19473721
[TBL] [Abstract][Full Text] [Related]
36. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.
Ku GY; Haaland BA; de Lima Lopes G
Lung Cancer; 2011 Dec; 74(3):469-73. PubMed ID: 21565418
[TBL] [Abstract][Full Text] [Related]
37. Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Yamaguchi H; Soda H; Nakamura Y; Takasu M; Tomonaga N; Nakano H; Doi S; Nakatomi K; Nagashima S; Takatani H; Fukuda M; Hayashi T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2011 Feb; 67(2):331-8. PubMed ID: 20401612
[TBL] [Abstract][Full Text] [Related]
38. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
[TBL] [Abstract][Full Text] [Related]
39. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y
Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420
[TBL] [Abstract][Full Text] [Related]
40. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
